Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2019 08:30 ET | Source: Veru Inc.

Veru Announces Successful Completion of Pre-NDA Meeting with FDA for TADFIN (Tadalafil 5mg and Finasteride 5mg) Combination for the Treatment of Benign Prostatic Hyperplasia

--Reached Agreement with FDA on Regulatory Package for NDA Submission Utilizing the 505(b)(2) Expedited Regulatory Pathway—-- TADFIN is a First Novel Combination Formulation of Tadalafil and...
June 04, 2019 08:00 ET | Source: Veru Inc.

Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA

— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market...
May 28, 2019 08:30 ET | Source: Veru Inc.

Veru to Present at the Jefferies 2019 Global Healthcare Conference on June 4th

MIAMI, May 28, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
May 15, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2019 Second-Quarter Financial Results

-- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –-- Strong Financial Results for Q2 and YTD FY 2019 ---- Company to Host Investor Conference Call on...
May 08, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 Second-Quarter Financial Results; Host Conference Call on May 15th

MIAMI, May 08, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer...
March 12, 2019 08:00 ET | Source: Veru Inc.

Veru to Participate in Two Investor Conferences in March

MIAMI, March 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology...
February 13, 2019 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2019 First Quarter Financial Results

-- Drug Development Advancing: Successful TADFIN Clinical Trial with NDA Filing in 2019; Two Prostate Cancer Clinical Trials Enrolling -- -- Company to Host Investor Conference Call on Wednesday,...
February 12, 2019 08:00 ET | Source: Veru Inc.

Veru Announces Scientific Presentations for Novel Prostate Cancer Drug Candidates at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium

MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology...
February 06, 2019 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2019 First-Quarter Financial Results, Host Conference Call on February 13th

MIAMI, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology...
January 22, 2019 08:30 ET | Source: Veru Inc.

Veru Initiates Clinical Trial for Proprietary, Novel, First-in-Class Drug for Advanced Prostate Cancer

--Open-Label Phase 1b/2 Clinical Trial Results Expected by Year-End-- -- Drug Addresses Significant Unmet Medical Need -- MIAMI, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:...